Astellas Moves For Ouster Of CV Board That Rejected Hostile Bid
This article was originally published in PharmAsia News
Executive Summary
The next time shareholders of U.S.-based CV Therapeutics meet, Astellas Pharma plans to move to oust four of CV's directors. No date has been set for that meeting to consider an Astellas offer to buy the firm that the directors rejected. Astellas said it would follow the ouster with a proposal to name two of the replacement directors. Astellas launched a hostile bid for the company in February. (Click here for more - a subscription may be required
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.